These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21229

  • 1. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY, Hata F, Ohashi T, Goldstein M.
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [Abstract] [Full Text] [Related]

  • 2. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
    Goldstein M, Lew JY, Hata F, Lieberman A.
    Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
    [Abstract] [Full Text] [Related]

  • 3. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M, Lieberman A, Battista AF, Lew JY, Hata F.
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [Abstract] [Full Text] [Related]

  • 4. Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?
    Fowler CJ, Thorell G, Andersson M, Magnusson O.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):12-9. PubMed ID: 2866447
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
    Silbergeld EK, Pfeiffer RF.
    J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
    [No Abstract] [Full Text] [Related]

  • 6. Antagonistic effects of apomorphine and haloperidol on rat striatal synaptosomal tyrosine hydroxylase.
    Christiansen J, Squires RF.
    J Pharm Pharmacol; 1974 May; 26(5):367-9. PubMed ID: 4152779
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P, Olianas MC, Gessa GL.
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [Abstract] [Full Text] [Related]

  • 8. [3H]dihydroergocryptine binding in rat brain.
    Davis JN, Strittmatter WJ, Hoyler E, Leefkowitz RJ.
    Brain Res; 1977 Aug 26; 132(2):327-36. PubMed ID: 196714
    [Abstract] [Full Text] [Related]

  • 9. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile.
    Bergmann F.
    Isr J Med Sci; 1982 Jan 26; 18(1):177-82. PubMed ID: 6121772
    [Abstract] [Full Text] [Related]

  • 10. Action of apomorphine, bromocriptine and lergotrile on gamma-aminobutyric acid and acetylcholine release in nucleus accumbens and corpus striatum.
    de Belleroche J, Gardiner IM.
    J Neural Transm; 1983 Jan 26; 58(3-4):153-68. PubMed ID: 6141217
    [Abstract] [Full Text] [Related]

  • 11. Dopamine receptors in the central nervous system.
    Seeman P, Tedesco JL, Lee T, Chau-Wong M, Muller P, Bowles J, Whitaker PM, McManus C, Tittler M, Weinreich P, Friend WC, Brown GM.
    Fed Proc; 1978 Feb 26; 37(2):131-6. PubMed ID: 414936
    [Abstract] [Full Text] [Related]

  • 12. Central monoamine synapses as sites of action for ergot drugs.
    Fuxe K, Ogren SO, Agnati LF, Andersson K, Hall H, Köhler C, Fredholm B.
    Adv Biochem Psychopharmacol; 1980 Feb 26; 23():41-62. PubMed ID: 6104914
    [Abstract] [Full Text] [Related]

  • 13. Effects of agonists and antagonists of D1 and D2 dopamine receptors on self-stimulation of the medial prefrontal cortex in the rat.
    Ferrer JM, Sanguinetti AM, Vives F, Mora F.
    Pharmacol Biochem Behav; 1983 Aug 26; 19(2):211-7. PubMed ID: 6138775
    [Abstract] [Full Text] [Related]

  • 14. Ergot alkaloids: interaction with presynaptic dopamine receptors in the neostriatum and olfactory tubercles.
    Marek KL, Roth RH.
    Eur J Pharmacol; 1980 Mar 21; 62(2-3):137-46. PubMed ID: 6769681
    [Abstract] [Full Text] [Related]

  • 15. Differential behavioral and biochemical effects of four dopaminergic agonists.
    Gianutsos G, Moore KE.
    Psychopharmacology (Berl); 1980 Mar 21; 68(2):139-46. PubMed ID: 6107946
    [Abstract] [Full Text] [Related]

  • 16. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
    Fuxe K, Agnati LF, Köhler C, Kuonen D, Ogren SO, Andersson K, Hökfelt T.
    J Neural Transm; 1981 Mar 21; 51(1-2):3-37. PubMed ID: 7264628
    [Abstract] [Full Text] [Related]

  • 17. The effect of butaclamol and of other neuroleptic agents on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity.
    Bronaugh RL, Tabak J, Ohashi T, Goldstein M.
    Psychopharmacol Commun; 1975 Mar 21; 1(5):501-10. PubMed ID: 7003
    [Abstract] [Full Text] [Related]

  • 18. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions.
    Markstein R.
    J Neural Transm; 1981 Mar 21; 51(1-2):39-59. PubMed ID: 6267192
    [Abstract] [Full Text] [Related]

  • 19. Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors.
    Schwarcz R, Fuxe K, Agnati LF, Hökfelt T, Coyle JT.
    Brain Res; 1979 Jul 20; 170(3):485-95. PubMed ID: 37986
    [Abstract] [Full Text] [Related]

  • 20. Dopaminergic modulation of hippocampal noradrenaline release. Evidence for alpha 2-antagonistic effects of some dopamine receptor agonists and antagonists.
    Jackisch R, Moll S, Feuerstein TJ, Hertting G.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug 20; 330(2):105-13. PubMed ID: 2995843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.